Recordati Industria Chimica e Farmaceutica SpA — Cyborg Score 7/10
Strong
Pharmaceuticals
Strategic Profile
Recordati uses strategic partnerships as part of its long-term growth strategy. The company operates two segments: Specialty and Primary Care, and Rare Diseases, with the bulk of profit derived from specialty and primary care including active ingredient production.
Cyborg Score Rationale
With a market cap of $11.5B and trailing twelve-month revenue of $2.82B, Recordati demonstrates solid financial performance. The company's dual-segment strategy targeting both common and rare diseases provides diversified revenue streams, though exposure to Europe limits geographic diversification.
Top Insights
The vast majority of company revenue is generated in Italy, followed by the United States, France, and Germany.
Lead pipeline candidates include REC 0551 for retinopathy of prematurity and LYNOVEX for cystic fibrosis exacerbations (both Phase 2), with REAGILA approved for schizophrenia.
The company operates two chemical plants and seven manufacturing sites worldwide with focus on continuously developing new specialties and medical innovations.
Recordati was acquired by CVC in July 2017, providing private equity backing for growth initiatives.
Named Competitors
Novartis — Diversified pharma with strong rare disease portfolio
Takeda Pharmaceutical — Global biopharmaceutical conglomerate
Cipla — Generic and specialty pharmaceuticals
Shionogi — Japanese pharmaceutical manufacturer
Recent Developments
(January 2026) Investment in STRM.BIO seed round indicating active venture involvement
(April 2025) Isturisa received expanded FDA approval for Cushing's Syndrome
(December 2024) Completed acquisition of global rights to Enjaymo from Sanofi, strengthening rare disease franchise
Open the full interactive Recordati Industria Chimica e Farmaceutica SpA report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.